Theratome Bio

Theratome Bio is a private, pre-revenue biotech company founded in 2018, transitioning from research to commercial focus in 2023. Its core technology involves AI-optimized, second-generation secretomes derived from adult stem cells, engineered for specific disease profiles by enhancing desired components and deleting others. The company's near-term pipeline targets organ transplant preservation and dry eye disease, with a longer-term interest in conditions like ARDS, ALS, and stroke, led by a team with deep expertise in vascular biology and cell therapy.

AI-enhanced platform for developing second-generation secretome therapies. Involves deriving bioactive factors (proteins, miRNAs, exosomes) from adult stem cells, optimizing them via specific stimulation, and selectively deleting undesirable components to create tailored formulations for specific diseases.

In organ preservation, Theratome will compete against existing cold storage solutions and other machine perfusion technologies. In dry eye disease, it faces numerous pharmaceutical and biologic competitors. Its key differentiation is its AI-refined, cell-free secretome approach within the broader regenerative medicine space.